APA (7th ed.) Citation

Cheng, X., Hübner, R., Kiedrowski, V. v., Fricker, G., Schirrmacher, R., Wängler, C., & Wängler, B. (2021). Design, synthesis, in vitro and in vivo evaluation of heterobivalent SiFAlin-modified peptidic radioligands targeting both integrin αvβ3 and the MC1 receptor: Suitable for the specific visualization of melanomas? Pharmaceuticals, 14(6), . https://doi.org/10.3390/ph14060547

Chicago Style (17th ed.) Citation

Cheng, Xia, Ralph Hübner, Valeska von Kiedrowski, Gert Fricker, Ralf Schirrmacher, Carmen Wängler, and Björn Wängler. "Design, Synthesis, in Vitro and in Vivo Evaluation of Heterobivalent SiFAlin-modified Peptidic Radioligands Targeting Both Integrin αvβ3 and the MC1 Receptor: Suitable for the Specific Visualization of Melanomas?" Pharmaceuticals 14, no. 6 (2021). https://doi.org/10.3390/ph14060547.

MLA (9th ed.) Citation

Cheng, Xia, et al. "Design, Synthesis, in Vitro and in Vivo Evaluation of Heterobivalent SiFAlin-modified Peptidic Radioligands Targeting Both Integrin αvβ3 and the MC1 Receptor: Suitable for the Specific Visualization of Melanomas?" Pharmaceuticals, vol. 14, no. 6, 2021, https://doi.org/10.3390/ph14060547.